Study Group: Medical Device Patent Experts: Lawyers (US)(?)
Council Members in this Study Group: 78
Request a survey with this Study Group
Leading Experts in this Study Group
![]() |
What is a GLG Leader? |
Stephen BentPartner & Co-Chair, Life Sciences
Foley & Lardner LLP
Stephen A. Bent is Partner and co-leader of the Life Sciences Industry Team at Foley & Lardner in Washington, DC. He is also a member of the Biotechnology & Pharmaceutical Practice Group and the Health Care and Nanotechnology Industry Teams. Mr. Bent specializes on the legal issues associated with biotechnology...
Patrick Joseph IgoeLife Sciences Patent Attorney
Independent IP Litigation Consultant
Patrick Joseph Igoe is a consultant and registered patent attorney in New York. His focus is patent issues throughout Life Sciences - for example, diagnostic/therapeutic assays; medical devices/imaging technologies; Rx antibiotics, biologics, drugs, and vaccines; and OTC medicines. His expertise includes...
Thomas SaundersPartner
Seyfarth Shaw LLP
Thomas Saunders is a Partner at Seyfarth Shaw in Boston, Massachusetts, where he specializes in representing emerging medical technology, biotechnology/genetic engineering and pharmaceutical concerns, particularly as to patent prosecution, patent strategy, IP licensing matters and ANDA Paragraph IV...
Marc ScheinesonPartner & Chair, Food and Drug Practice
Alston & Bird LLP
Marc Scheineson is a Partner with Alston & Bird where he heads the firm's Food and Drug Law Practice. He has practiced food and drug law, health care law and administrative law for over 20 years in national law firms and at the FDA. His practice focuses on determining the regulatory course of least...
Ted FrankResident Fellow & Director, Legal Center
American Enterprise Institute For Public Policy Research
Ted Frank is Resident Fellow and Director of the American Enterprise Institute Legal Center for the Public Interest in Washington, DC. Mr. Frank manages the Institute's research in and studies liability reform. His research areas include products liability (including pharmaceuticals and asbestos), class...
John RyanPartner
Crowell & Moring LLP
John W. Ryan is a Partner at Crowell & Moring in Washington, DC, where he focuses on the chemical, biotechnology, medical device, and pharmaceutical industries. As the former Vice President and Chief Patent Counsel for IGEN International, he has managed various patent portfolios. Previously, Mr. Ryan...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Experts(?)
* As noted in the Wall Street Journal article, Aricept® is a blockbuster drug for the treatment of Alzheimer's disease. And, as noted in Judge Ackerman's ruling, Aricept sales are a huge source of Eisai's revenue - "sales of Aricept® in the United States constitute 70% of Eisai’s...
(1) The US Court of Appeals for the Federal Circuit - in a complicated 22-page split Opinion earlier today Wed 19 Mar 2008 - provided Amgen another victory in its long patent battle(s) with Hoffmann-LaRoche. (2) Amgen's Aranesp® and EPOGEN® (each a prescription only product...
Product shelf-life is a major economic concern for the agricultural industry. The biological mechanism for regulating the ripening of fruits is mediated by ethylene. Ethylene management is addressed in three ways: 1) Ethylene...
I discuss this issue (and other FACTA-related issues) at length in my latest Liability Outlook.
The at-risk product launch by [NasdaqGS:TEVA] Teva of generic equivalents to [NYSE:PFE] Pfizer's Neurontin® (gabapentin) might - and the emphasis is clearly on might - yet prove to be an expensive mistake by Teva. The recent Opinion by the United States Court of Appeals for the Federal Circuit...
Most Common Company Types:
- Law Firm (general practice/large)
- Law Firm (Boutique / Specialized)
Most Common Job Types:
- Partner
- Director
- Attorney
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms


